Holen Sie sich die Stockscreener-App
4.40
2.09%
0.09
Polypid Ltd Aktie (PYPD) Neueste Nachrichten
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026 - markets.businessinsider.com
PolyPid to present D-PLEX100 pharmacokinetic data at ESCMID Global By Investing.com - Investing.com India
In a Phase 3 surgery trial, PolyPid's antibiotic released for 32 days - Stock Titan
Short Covering: How much upside does PolyPid Ltd have2026 Key Lessons & Weekly High Return Stock Forecasts - baoquankhu1.vn
PYPD Options Volatility — NASDAQ:PYPD - TradingView — Track All Markets
PYPD Options Chain — NASDAQ:PYPD - TradingView — Track All Markets
Market Rankings: Is PolyPid Ltd likely to announce a buybackPortfolio Gains Summary & Smart Swing Trading Techniques - baoquankhu1.vn
PYPD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Gainers: Does PolyPid Ltd have high return on assets2026 Technicals & Target Return Focused Stock Picks - baoquankhu1.vn
PolyPid Ltd. (NASDAQ:PYPD) Q4 2025 earnings call transcript - MSN
PolyPid (PYPD) director submits initial Form 3 ownership - Stock Titan
PolyPid (PYPD) director details vested and future stock options - Stock Titan
Total equity of PolyPid Ltd. – FWB:2PV - TradingView
Total debt of PolyPid Ltd. – FWB:2PV - TradingView
PolyPid Ltd. Balance Sheet – FWB:2PV - TradingView
Cash per share of PolyPid Ltd. – FWB:2PV - TradingView — Track All Markets
PolyPid Ltd. Stock (2PV)Quote Deutsche Boerse AG - marketscreener.com
PolyPid Ltd.: Target Price Consensus and Analysts Recommendations | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Revenue and Earnings Analysts Forecasts Revisions | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Financial Data Forecasts Estimates and Expectations | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Shareholders Board Members Managers and Company Profile | IL0011326795 - marketscreener.com
PolyPid Ltd.: Fundamental Analysis and Financial Ratings | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Performance & Quotes, 2PV Stock Price on Deutsche Boerse AG Exchange - marketscreener.com
Taxes of PolyPid Ltd. – FWB:2PV - TradingView
2PV: Static price chart | PolyPid Ltd. | IL0011326795 - marketscreener.com
Net income of PolyPid Ltd. – FWB:2PV - TradingView
2PV Stock Price and Chart — FWB:2PV - TradingView
PolyPid begins rolling NDA submission for surgical infection drug By Investing.com - Investing.com South Africa
PYPD Should I Buy - Intellectia AI
Polypid Ltd Initiates D-Plex100 Nda Submission to Fda - MarketScreener
PolyPid’s Moment Is Here: NDA Submission Begins as a High-Impact Catalyst Stack Takes Shape (NASDAQ: PYPD) - TipRanks
Risk Check: Does PolyPid Ltd stock benefit from AI growth2026 Performance Recap & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Polypid initiates D-Plex100 NDA submission to the FDA - marketscreener.com
PolyPid begins rolling NDA submission for surgical infection drug - Investing.com
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA - Bitget
PolyPid (PYPD) advances Fast Track NDA for D-PLEX100 after strong Phase 3 data - Stock Titan
Aug Closing: How does PolyPid Ltd score in quality rankingsFed Meeting & Low Risk Entry Point Tips - baoquankhu1.vn
Insider Buy: Does PolyPid Ltd have high return on assetsBear Alert & Short-Term Swing Trade Alerts - baoquankhu1.vn
Patterns Watch: How much upside does PolyPid Ltd haveMarket Volume Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn
PolyPid Ltd Stock: Innovative Drug Delivery Solutions in a Competitive Biotech Landscape - AD HOC NEWS
PolyPid (PYPD) COO details stock option and share holdings - Stock Titan
PolyPid (PYPD) director Dror-Darwish Nir lists six vested option grants - Stock Titan
PolyPid (PYPD) CFO details extensive employee stock option awards - Stock Titan
PolyPid (PYPD) director Barenholz discloses shares and multiple option grants - Stock Titan
PolyPid (PYPD) director Joseph BenAmram reports initial stock option grants - Stock Titan
Pullback Watch: Whats the beta of PolyPid Ltd stock2026 Risk Factors & Verified Short-Term Trading Plans - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: PolyPid (PYPD), Axsome Therapeutics (AXSM) - The Globe and Mail
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
PolyPid (PYPD) director discloses stock options on 17,456 shares - Stock Titan
PolyPid (PYPD) director details shares and vested stock options - Stock Titan
PolyPid (PYPD) CEO details stock and option holdings in Form 3 - Stock Titan
PolyPid (PYPD) deputy CEO discloses extensive employee stock options - Stock Titan
PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention - TipRanks
PolyPid receives $4.3M FDA fee waiver for D-PLEX100 application By Investing.com - Investing.com India
PolyPid receives $4.3M FDA fee waiver for D-PLEX100 application - Investing.com Canada
Is PolyPid Ltd likely to announce a buybackEarnings Growth Report & Step-by-Step Trade Execution Guides - baoquankhu1.vn
PolyPid granted $4.3M waiver from FDA for D-Plex application - TipRanks
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):